Antithrombosis trials: Should we test therapeutic heparin adjusted based on activated partial thromboplastin time in septic shock?

Critical Care Medicine

Volumn 37, Issue 4, 2009, Pages 1486-1487

  Barochia, Amisha V ^a   Li, Yan ^a   Cui, Xizhong ^a   Sweeney, Daniel A ^a   Natanson, Charles ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Heparin; Sepsis; Treatment

Indexed keywords

ANTITHROMBIN III; DROTRECOGIN; HEPARIN; PLACEBO; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEPARINIZATION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; THERAPY EFFECT; THROMBOSIS; TREATMENT OUTCOME;

ANTICOAGULANTS; HEPARIN; HUMANS; PARTIAL THROMBOPLASTIN TIME; SHOCK, SEPTIC;

EID: 67650504236     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819d2bb4     Document Type: Editorial

References (20)

1. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
2. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-1878
3. Davidson BL, Geerts WH, Lensing AW: Lowdose heparin for severe sepsis. N Engl J Med 2002; 347:1036-1037
4. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
5. Jaimes F, De La Rosa G, Morales C, et al: Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37:1185-1196
6. Minneci PC, Deans KJ, Cui X, et al: Antithrombotic therapies for sepsis: A need for more studies. Crit Care Med 2006; 34: 538-541
7. Hirsh J, Bauer KA, Donati MB, et al: Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):141S-159S
8. Zarychanski R, Doucette S, Fergusson D, et al: Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36:2973-2979
9. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
10. Abraham E, Reinhart K, Svoboda P, et al: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-2089
11. Baudo F, Caimi TM, de Cataldo F, et al: Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336-342
12. Bernard GR, Ely EW, Wright TJ, et al: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29: 2051-2059
13. Eisele B, Lamy M, Thijs LG, et al: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, doubleblind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24:663-672
14. Fourrier F, Chopin C, Huart JJ, et al: Doubleblind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104:882-888
15. Inthorn D, Hoffmann JN, Hartl WH, et al: Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 1997; 8:328-334
16. Nadel S, Goldstein B, Williams MD, et al: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007; 369: 836-843
17. Balk RA, Bedrosian C, McCormick L, et al: Prospective, double-blind, placebocontrolled, trial of ATIII substitution in sepsis. Intensive Care Med 1995; 21(Suppl 1): S17
18. Evaluate protein C levels in severe sepsis patients on drotrecogin alfa (activated). Available at: http://clinicaltrials.gov/ct2/show/NCT00386425. Accessed February 11, 2008
19. Efficacy and safety of drotrecogin alfa (activated) in adult patients with septic shock. Available at: http://clinicaltrials.gov/ct2/show/NCT00604214. Accessed February 11, 2008
20. Activated protein C and corticosteroids for human septic shock (APROCCHS). Available at: http://clinicaltrials.gov/ct2/show/NCT00625209. Accessed February 11, 2008